GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026ByKyle Doherty June 9th 2026
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma ByAshling Wahner June 8th 2026
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026ByChris RyanJune 4th 2026
Darovasertib Plus Crizotinib Delivers PFS Gains in HLA-A2–Negative Metastatic Uveal MelanomaByCaroline SeymourJune 1st 2026